

PRODUCT: BGT226

ALTERNATE NAMES: BGT 226; BGT-226; NVP-BGT226; NVPBGT226; NVP BGT226; (Z)-but-2-enedioic acid;8-(6-methoxypyridin-3-yl)-3-methyl-1-[4-piperazin-1-yl-3-(trifluoromethyl)phenyl]imidazo[4,5-c]quinolin-2-one; 1-(3-(Trifluoromethyl)-4-(piperazin-1-yl)phenyl)-8-(6-methoxypyridin-3-yl)-3-methyl-1H-imidazo[4,5-c]quinolin-2(3H)-one maleic acid salt

CATALOG#: B1719-1, -5

AMOUNT: 1 mg, 5 mg

STRUCTURE:



MOLECULAR FORMULA: C₃₂H₂₉F₃N₆O₆

MOLECULAR WEIGHT: 650.6

CAS NUMBER: 1245537-68-1

APPEARANCE: Solid powder

SOLUBILITY: DMSO

PURITY: >98%

STORAGE: Dry, dark and at 4°C for short term (days to weeks) or at -20°C for long term. Protect from air and light.

DESCRIPTION: BGT226 (NVP-BGT226) is a novel inhibitor of class I PI3K/mTOR with IC₅₀ values of 4 nM, 63 nM and 38 nM for PI3K α , PI3K β and PI3K γ , respectively.

REFERENCES:

- Baumann P et al. Simultaneous targeting of PI3K and mTOR with NVP-BGT226 is highly effective in multiple myeloma. *Anticancer Drugs*, 2012, 23(1), 131-138.
- Markman B et al. Phase I safety, pharmacokinetic, and pharmacodynamic study of the oral phosphatidylinositol-3-kinase and mTOR inhibitor BGT226 in patients with advanced solid tumors. *Ann Oncol*, 2012, 23(9), 2399-2408.
- Chang KY et al. Novel phosphoinositide 3-kinase/mTOR dual inhibitor, NVP-BGT226, displays potent growth-inhibitory activity against human head and neck cancer cells in vitro and in vivo. *Clin Cancer Res*, 2011, 17(22), 7116-7126.

RELATED PRODUCTS:

- BEZ235 (NVP-BEZ235) (Cat. No. 1626-5, 25)
- BI-D1870 (Cat. No. 1824-1, 5)
- Deforolimus (Cat. No. 1587-5, 25)
- DiscoveryPak™ PI 3-Kinase Inhibitor Panel (Cat. No. K856-5)
- Everolimus (Cat. No. 1917-5, 25)
- GDC-0941 (Cat. No. 1623-1, 5)
- GSK-2126458 (Cat. No. 1961-1, 5)
- IC87114 (Cat. No. 1661-1)
- LY 294002 (Cat. No. 1667-5, 25)
- OSI-027 (Cat. No. 2372-5, 25)
- mTOR Inhibitor, Ku-0063794 (Cat. No. 1779-1, 5)
- mTOR Inhibitor, WYE-28 (Cat. No. 2255-500, 1000)
- mTOR Inhibitor, WYE-132 (Cat. No. 2256-500, 1000)
- mTOR Inhibitor, WYE-23 (Cat. No. 2257-500, 1000)
- PI-103 (Cat. No. 1728-1, 5)
- PI3-Ky Inhibitor, AS-605240 (Cat. No. 1780-1, 5)
- PathwayReady™ PI3-K/Akt/mTOR Signaling Inhibitor panel (Cat. No. K857-11)
- PP242 (Cat. No. 1658-1)
- P529 (Cat. No. 2462-5, 25)
- PX-866 (Cat. No. 1965-1,5)
- Rapamycin (Cat. No. 1568-5, 50)
- EZSolution™ Rapamycin (Cat. No. 1746-5)
- Temsirolimus (Cat. No. 1600-5, 25)
- TGX-115 (Cat. No. 1660-1)
- TGX-221 (Cat. No. 1781-1, 5)
- Torin 1 (Cat. No. 2273-5, 25)
- Torin 2 (Cat. No. 2274-5, 25)
- EZSolution™ Torin 1 (Cat. No. 2353-5)
- EZSolution™ Torin 2 (Cat. No. 2354-5)
- Wortmannin (Cat. No. 1670)
- XL765 (Cat. No. 2551-5, 25)

USAGE:

FOR RESEARCH USE ONLY! Not to be used in humans